All articles tagged with #triple negative breast cancer
Researchers developed a targeted antibody against SFRP2 that disrupts survival mechanisms of triple-negative breast cancer, reprograms immune cells to fight the tumor, and shows promise in preclinical models, including resistant and metastatic cases, paving the way for potential new treatments.
Research from Monash University suggests that cheap blood pressure drugs called beta blockers may help slow the progression of aggressive triple-negative breast cancer by inhibiting a gene called HOXC12, potentially offering a low-cost treatment option. Further studies are needed to confirm if this approach can be used at diagnosis to identify patients who would benefit from beta blocker therapy.
Research suggests that beta-blockers, commonly used for blood pressure, may help prevent the spread of aggressive triple-negative breast cancer by turning off the HOXC12 gene, potentially improving survival outcomes for patients with this difficult-to-treat cancer.
A study found that the anti-nausea drug aprepitant is associated with improved survival and reduced recurrence in women with early-stage breast cancer, especially in those with the aggressive triple-negative subtype, suggesting potential for broader use during chemotherapy.
Scientists in Australia have developed a new oral drug, CDDD11-8, which shows promise in halting the growth of aggressive triple-negative breast cancer by selectively inhibiting the CDK9 pathway that cancerous cells rely on for survival and growth. Unlike chemotherapy, this drug targets only cancerous cells within breast tissue and metastatic lesions, showing potential for improved survival rates without toxic side effects on healthy cells. The drug has demonstrated success in animal models and patient-derived breast cancer tissue, offering hope for a new targeted treatment option for this deadly form of breast cancer.
Anixa Biosciences is developing a potentially game-changing vaccine that could prevent the recurrence of the most aggressive form of breast cancer, triple-negative breast cancer. The vaccine, developed by the late Dr. Vincent Tuohy, is currently being tested on women diagnosed with this type of breast cancer. If successful, the vaccine could hit the market within the next five years. The team has received FDA approval to begin human testing in 2021 and is currently conducting a trial with promising results. The goal is to eventually test the vaccine on women with other types of breast cancer and explore its potential for cancer prevention in those who have never had the disease.
Scientists have made a major breakthrough in treating Triple Negative Breast Cancer (TNBC), an aggressive form of breast cancer, by developing a vaccine that targets the cancer cells. The vaccine successfully produced a T Cell Immune response in patients during trials and showed minimal side effects. Researchers are now looking to further study the treatment to potentially prevent more severe treatments like mastectomies and to address the unmet need for targeted treatment options for TNBC.
A vaccine targeting triple-negative breast cancer has shown promising results in its first clinical trial, with no side effects and a 75% immune response rate in patients. The vaccine, developed by Anixa Biosciences, targets a lactation protein called α-lactalbumin found in the majority of triple-negative breast cancer patients. The vaccine aims to prevent the recurrence of this aggressive form of cancer in those who have already been treated and may also be used to treat tumors in women who have not yet undergone treatment. Further research is needed, but the vaccine could potentially be available within the next five years.
A Phase 1 clinical trial of a vaccine targeting triple negative breast cancer (TNBC), an aggressive and difficult-to-treat form of breast cancer, has shown promising results. The trial involved 16 patients who received three doses of the vaccine, with the majority developing a strong immune response and experiencing no major side effects. TNBC lacks receptors for progesterone, estrogen, and the HER2 protein, making it resistant to traditional breast cancer treatments. The vaccine targets a protein called α-lactalbumin, which is present in most TNBC tumors. Further trials are planned to test the vaccine in combination with an immunotherapy drug and to assess its safety in high-risk patients.
A new vaccine targeting triple-negative breast cancer is showing promise in early clinical trials, with no significant side effects and a good immune response observed in 75% of patients. The vaccine, developed by Anixa Biosciences, aims to direct the immune system to destroy TNBC cancer cells through a unique mechanism. The Phase 1 trial involved 16 women who received three vaccinations, and the next phase will focus on preventing the onset of triple-negative breast cancer. While the vaccine is a promising development, it may take around five years before it becomes available to the general public.
A new vaccine targeting triple-negative breast cancer is showing promise in early clinical trials, with no significant side effects and a good immune response observed in 75% of patients. The vaccine, developed by Anixa Biosciences, aims to prevent cancer recurrence in patients who have already been treated for triple-negative breast cancer. While the vaccine is a promising development, it may take around five years before it becomes available to the general public. The vaccine is part of the growing field of immunotherapy, which harnesses the immune system to fight cancer.
Doreen Wesley and her daughter Madeline Mordarski from Ohio both battled breast cancer, with Doreen being diagnosed in 2015 and Madeline in 2022. Doreen underwent chemotherapy, radiation, and a double mastectomy, while Madeline faced the most aggressive form of breast cancer, triple-negative breast cancer (TNBC). Madeline credited her mother's illness for early detection of her own cancer. Both mother and daughter supported each other through their treatments, with Madeline finding support groups for young TNBC patients. In July, Madeline was declared cancer-free, but will continue maintenance chemotherapy. Breast cancer is the most common form of cancer, and early detection is crucial for successful treatment.
Three women diagnosed with triple-negative breast cancer (TNBC) are being recognized as Hometown Heroes through Merck's Uncovering TNBC program for raising awareness and advocating for at-risk women in their communities. TNBC is an aggressive form of breast cancer that disproportionately affects Black women. Health care disparities, including limited access to screenings and treatment, contribute to higher death rates among Black women. The women emphasize the importance of education, support, and storytelling to empower women and address disparities in breast cancer care.
Jennifer Davis, the first person in the world to receive a groundbreaking vaccine to prevent triple-negative breast cancer, shares her story. After being diagnosed with triple-negative breast cancer in 2018, undergoing intense treatment and surgeries, and living in fear of relapse, Davis opted to participate in human trials for the new vaccine in 2021. The vaccine, developed by researchers at the Cleveland Clinic, targets a lactation protein found in most cases of triple-negative breast cancer and is designed to prompt the immune system to attack cancerous cells and prevent tumor growth. Davis has experienced no major side effects and hopes that the vaccine will prevent her cancer from recurring, providing her with a newfound sense of peace and the opportunity to live life to the fullest.
Brian Skoczylas, the husband of Kim Skoczylas, a Livonia mother of three who tragically lost her battle with triple-negative breast cancer, shares her story to raise awareness about the importance of early detection. Kim's cancer was initially misdiagnosed as a cyst due to her young age, but it later returned aggressively. Despite undergoing treatment and a double mastectomy, Kim's cancer spread to her back, liver, and bones. Brian is grateful for the support and donations that will help raise their young children and hopes that sharing Kim's story will encourage others to get mammograms and prevent similar tragedies.